Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder Jan 11, 2021
Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Dec 17, 2020
Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments Dec 10, 2020
Adial Pharmaceuticals Enters Agreement to Acquire Purnovate, a Developer of Potential Therapies for Non-Opioid Pain Reduction and Treatment of Addiction Dec 10, 2020
Adial Pharmaceuticals CEO Weighs in on the Alcohol Pandemic and Drunk Driving Over the Holidays; FOX31 Denver's Shaul Turner Interviews Bill Stilley Dec 9, 2020
Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured in Follow-up TV News Story Dec 4, 2020
Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured on Multiple Television News Outlets Nov 25, 2020
Adial Pharmaceuticals Enters into Common Stock Purchase Agreement with Keystone Capital Partners to Support Strategic Opportunities and Future Growth Initiatives Nov 25, 2020
